Doer BioSecures Sixth Consecutive Spot on Hangzhou's Unicorn List and Files IPO Prospectus
Doer Biologics
Biological Drug Developer
On April 23, 2026, the tenth Everything Grows Conference was held in Hangzhou. At the conference, the Hangzhou Entrepreneurship and Investment Association, in collaboration with Weilian and Hangzhou Bank, officially released the "2026 Hangzhou Unicorn and Quasi-Unicorn Enterprise List." Zhejiang Doer Biologics Co., Ltd. once again made it onto the list of Hangzhou's quasi-unicorn enterprises, marking the sixth time that Doer Biologics has received this honor.
The list shows that in Hangzhou's quasi-unicorn enterprises, the life health sector ranks first among the top ten fields with 118 companies. Doer Biologics' continuous inclusion in the list from 2021 to 2026 is not only a sustained recognition of the company’s R&D strength and innovation development potential, but also the greatest encouragement for its commitment to independent innovation and relentless efforts!
In addition to being a high-tech enterprise and a company with strong intellectual property, the company also hosts a national postdoctoral research workstation and provincial R&D centers, among others. Five innovative drug projects have successfully entered the clinical research stage. Looking ahead, Doer Biologics will continue to focus on researching multi-specificity innovative biologics based on multi-domain structures, continuously developing innovative biologics with proprietary intellectual property rights to address unmet clinical needs. Meanwhile, adhering to the rigorous "DOER" scientific spirit, with the corporate vision of contributing to human health through diligent and innovative work, the company is committed to the development of innovative biologic drugs. Through the team's accumulated efforts, Doer Biologics aims to contribute to human health!
About Doer
Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics") is a clinical-stage biopharmaceutical company focused on the discovery and development of multi-specific biotherapeutics based on multi-domain structures to address unmet medical needs in the fields of metabolic diseases and cancer.
For more information about Doer Biologics, please visit www.doerbio.com or contact bd@doerbio.com.